




RealRate

PHARMACEUTICAL 2015

Actinium Pharmaceuticals Inc
Rank 249 of 274



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Actinium Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Actinium Pharmaceuticals Inc compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 7.2% points. The greatest weakness of Actinium Pharmaceuticals Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 85% points.

The company's Economic Capital Ratio, given in the ranking table, is 56%, being 198% points below the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	7,407
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,492
Liabilities, Non-Current	0
Other Assets	35
Other Compr. Net Income	0
Other Expenses	38
Other Liabilities	0
Other Net Income	-2,207
Other Revenues	0
Property and Equipment	128
Research and Development	12,267
Selling, General and Administrative Expense	10,175

Output Variable	Value in 1000 USD
Assets	7,569
Liabilities	9,492
Expenses	22,481
Revenues	0
Stockholders Equity	-1,923
Net Income	-24,688
Comprehensive Net Income	-24,688
BaseVar	20,874
ECR before LimitedLiability	-339%
Economic Capital Ratio	56%